SCHEMBL2950317

SCHEMBL2950317

Cc1ccc(-n2c(=O)ccc3c(Nc4ccc(F)c(C)c4)c(C(N)=O)sc32)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.39
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
MAPT P10636 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
CHRNA7 P36544 2/20 0.37
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
IDO1 P14902 2/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
GAA P10253 1/20 0.35
PTPN7 P35236 1/20 0.35
TDO2 P48775 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2958462 0.94 CSF1R (0.39) CSF1RMAPTCHRNA7ADORA3ADORA2A
SCHEMBL2952198 0.92 CSF1R (0.39) CSF1RMAPTCHRNA7MEN1KMT2A
SCHEMBL2952191 0.88 CSF1R (0.40) CSF1RALDH1A1MAPTCHRNA7KMT2A
SCHEMBL2947364 0.86 CHRNA7 (0.40) CSF1RALDH1A1HPGDCHRNA7MEN1
SCHEMBL2958644 0.85 RAB9A (0.39) CSF1RALDH1A1HPGDMAPTAPOBEC3G
Ammonia Solution, Strong SCHEMBL2958892 0.83 CHRNA7 (0.35) CSF1RMAPTCHRNA7IDO1MEN1
SCHEMBL1266478 0.83 CHRNA7 (0.35) CSF1RMAPTCHRNA7IDO1MEN1
SCHEMBL2955910 0.83 CHRNA7 (0.44) CSF1RMAPTCHRNA7GAA
SCHEMBL1267372 0.83 CHRNA7 (0.36) CSF1RALDH1A1HPGDMAPTCHRNA7
SCHEMBL2949616 0.83 DRD4 (0.40) CSF1RALDH1A1HPGDMAPTCHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK CSF1R 412/4885ALDH1A1 1045/4885HPGD 3282/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 CSF1R 328/4885ALDH1A1 717/4885HPGD 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.